Examining endogenous dopamine in treated schizophrenia using [C-11]-(+)-PHNO positron emission tomography: A pilot study

作者：Caravaggio Fernando; Borlido Carol; Wilson Alan; Graff Guerrero Ariel^*

来源：Clinica Chimica Acta, 2015, 449: 60-62.

DOI：10.1016/j.cca.2015.03.020

• PET
• Dopamine
• D2/3R
• Schizophrenia

Background: Using positron emission tomography (PET) it is possible to estimate endogenous dopamine (DA) occupying D-2/3 receptors (D2/3R) in the living human brain. Persons with schizophrenia (SZ) (previously medicated and nave) have increased endogenous DA occupying D2/3R in the caudate. It is unknown whether currently medicated patients demonstrate increased DA levels at D2/3R. Moreover, DA levels have not been estimated in SZ using agonist radiotracers, which may offer a more sensitive quantification over antagonists.
Methods: Using the agonist radiotracer [C-11]-(+)-PHNO, DA levels were estimated at D2/3R (Delta BPND) in three patients with SZ (male, mean age = 30 +/- 16). Patients were currently being treated long-term with Olanzapine (147 +/- 88 nmol/L). Results were compared to ten healthy controls (HCs).
Results: Medicated persons with SZ had greater ABPND in the left caudate (U = 2, Z = -2.20, p = .03) and right putamen (U = 2, Z = 220, p = .03). No differences were observed in the ventral striatum or globus pallidus.
Conclusions: It is possible to estimate endogenous DA at D2/3R in SZ patients currently taking antipsychotics. Despite medication, patients continue to have increased endogenous DA at D2/3R This lends more biological support to the clinical observation that relapses in symptoms can occur in the face of complete antipsychotic discontinuation. Future studies with larger samples are warranted.

• 出版日期2015-9-20
• 单位河北医科大学